| Amirhossein Sahebkar | |
| Native Name: | امیرحسین صاحبکار |
| Native Name Lang: | fa |
| Fields: | Medical biotechnology, cardiovascular disease |
| Workplaces: | Mashhad University of Medical Sciences |
| Education: | Mashhad University of Medical Sciences (PharmD, PhD) |
| Thesis1 Title: | and |
| Thesis2 Title: | )--> |
| Thesis1 Url: | and |
| Thesis2 Url: | )--> |
| Thesis1 Year: | and |
| Thesis2 Year: | )--> |
| Doctoral Advisors: | )--> |
| Spouses: | )--> |
| Partners: | )--> |
Amirhossein Sahebkar is an Iranian biotechnologist specializing in cardiovascular diseases. He is a faculty member in the department of medical biotechnology at the Mashhad University of Medical Sciences.
Sahebkar completed a Pharm.D. in 2008 from Mashhad University of Medical Sciences.[1] His dissertation was titled, An investigation of serum antibody titres to heat shock protein 27 (anti- Hsp27) as a biomarker for the detection of acute coronary syndrome. Sahebkar earned a Ph.D. in pharmaceutical biotechnology from the Mashhad University of Medical Sciences. His dissertation was titled, Preparation and evaluation of nanoliposomes conjugated with apolipoprotein B-100 antibodies as a therapeutic option for serum LDL reduction. He completed a postdoctoral fellowship in cardiometabolic diseases at the University of Western Australia.[2]
Sahebkar is a faculty member in the department of medical biotechnology at the Mashhad University of Medical Sciences.[3] His research focuses on cardiovascular disease, atherosclerosis, and blood lipids. He is a member of the Iran's National Elites Foundation. In 2016, he was presented the Professor Dr. Fereydoun Azizi award by the Iranian Academy of Medical Sciences.